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ABSTRACT
Hypercortisolism attributable to hypersecretion of ACTH by a pi­
tuitary adenoma is an uncommon and progressively lethal disease. 
Because of its rarity, it has been difficult to collect a large series of 
patients in order to identify the prognostic factors influencing the 
outcome after transsphenoidal surgery. We conducted a multicenter, 
retrospective analysis of the early and late results of surgical treat­
ment of Cushing’s disease.
Files of patients with. Cushing’s disease who underwent trans­
sphenoidal surgery between 1975 and 1990 were collected from 25 
institutions throughout Europe. Data from 668 of 716 patients were 
suitable for statistical analyses. Surgical mortality was 1.9%, and 
major morbidity occurred in 97 patients (14,5%), Clinical and bio­
chemical remission of Cushing’s disease after surgery occurred in 510 
cases (76.3%). Identification of the tumor by neuroradiological imag­
ing or at operation with histopathological corroboration was associ­
ated with remission of hypercortisolism. Recurrence of the disease 
occurred in 65 (12,7%) of 510 patients in remission after surgery at 
a mean time of 39.3 months (range 6 -1 0 4  months). The distribution 
of the recurrences did not show any apparent plateau or cluster 
throughout the follow-up period. Low postoperative steroid levels, 
absence of cortisol response to CRH, and the need for long-term 
glucocorticoid substitution therapy were all associated with a high 
probability of long-term remission,
Our study demonstrates that transsphenoidal surgery is  a safe and 
effective treatment for patients with Cushing’s disease. However, 
after successful surgery there is a steady increase in the percentage 
of recurrences, which continues with time. Patients who after oper­
ation had hypoadrenocorticism and needed long-term glucocorticoid 
substitution therapy had the lowest risk of relapse. (J Clin Endocrinol 
Metab 80: 3114-3120, 1995)
Hy p e r c o r t is o l is m  attributable to overproduction ofACTH by a pituitary adenoma (Cushing's disease) is rare. Its incidence in the general population is estimated to
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ease (3). Other therapeutic options, such as bilateral adre­
nalectomy (4,5), medical therapy with adrenostatic drugs (6), 
radiotherapy (7), and radiosurgery (8), have been proposed 
either as alternatives to pituitary surgery or as adjunctive 
therapy in cases of incomplete remission of the disease after 
operation. In the last decade, several institutions have re­
ported the results of transsphenoidal surgery in patients with 
Cushing's disease. Although most authors describe a remis­
sion rate of 70-90%, the only other available retrospective 
multicenter survey reported considerably less favorable re­
sults in centers in the United States (9). Moreover, an in­
creasing rate of late recurrence of the disease to as high as 
20% at 5-6 yr has been reported, especially in those series 
with the longest follow-up (10-13). The rarity of Cushing's 
disease has precluded the collection of a large series of pa­
tients undergoing transsphenoidal operation in the same 
institution, thus making it difficult to assess the preoperative 
and postoperative factors influencing the immediate and late 
outcome of the disease. To address this problem, we carried 
out a retrospective, multicenter study in European countries 
in order to gather enough patients who had undergone sur­
gery for Cushing's disease, thus allowing us to perform a 
meaningful analysis of the possible prognostic factors linked 
to either failure or recurrence.
Materials and Methods
Study design
Endocrine and neurosurgical centers throughout Europe were asked 
to participate in a retrospective study on the surgical treatment of Cush­
ing's disease; a study protocol was elaborated, discussed, and amended 
by all participants, and a questionnaire was prepared accordingly (a 
copy is available on request).
All consecutive patients at each center were included in the study 
when the following criteria were met: 1) planned transsphenoidal sur­
gery for suspected Cushing's disease. Criteria for the diagnosis of Cush­
ing's disease were not explicitly given because of the great variability of 
the diagnostic tests used in the different countries during the period of 
the study. However, from a survey conducted among the participating 
centers, patients were diagnosed to have Cushing's disease on the basis 
of at least the clinical picture and the lack of steroid suppression during 
low-dose dexamethasone administration, Patients for whom an opera­
tion had been scheduled but not completed because of technical failure 
or patients who were later found to harbor an ectopic ACTH-secreting 
tumor were also included on an intention-to-treat basis; 2) operation 
performed between January 1,1975, and December 31, '1990. The former 
limit was chosen because microsurgical removal of pituitary tumors was 
not common before 1975; and 3) no prior pituitary surgery.
The questionnaire had five sections. The first contained the general 
demographic data of the patient and the presumed year of onset of the 
disease. The second section contained endocrinological data (baseline 
cortisol, ACTH, and urinary steroid levels; ACTH and steroid responses 
to TRH/GnRH and to corticotropin-releasing hormone (CRH) admin­
istration; and results of bilateral inferior petrosal sinus sampling) and 
neuroradiological characteristics [plain skull radiography, computed 
tomography (CT) scan, and magnetic resonance imaging (MRI)]. The 
third section concerned surgical characteristics (date of surgery, type of 
surgery, and diameter, location, invasiveness, and histological confir­
mation of a pituitary lesion), early endocrinological postoperative eval­
uation, and the need for and the duration of postoperative glucocorticoid 
substitution therapy. The fourth section referred to the last available 
follow-up information (date of last visit; baseline cortisol, ACTH, and 
urinary steroid levels; present status of the patient and in the case of 
death, date and cause). If the patient had a clinical and biochemical 
recurrence of Cushing's disease after successful operation, participants 
were asked to complete the fifth section of the questionnaire concerning
the endocrinological and neuroradiological characteristics of the patient 
at relapse.
Hormonal data were described qualitatively as high, normal, or low  
according to the reference limits applied in each center. Similarly, re­
sponses to stimulation tests were described as normal, high, or no 
response, as the large time span of the study and the different methods 
used throughout Europe for the measurement of hormone levels pre­
vented the possibility of any meaningful quantitative analysis. How­
ever, to keep the results as homogeneous as possible, general criteria for 
determining normal and pathological responses were given, Thus, an 
increment of ACTH levels of at least 50% over baseline or an increase 
of cortisol concentrations of at least 160 nm ol/L after the administration 
of TRH/GnRIi or both were required to define a paradoxical response 
to this test. Participants were requested to specify the criteria they used 
for classifying the response to the CRH test (ovine or human). ACTH and 
cortisol increments lower than 50% over baseline after CRH adminis­
tration were regarded as indicating no response. There was more vari­
ability in the definition of the upper normal limit because this is visually 
derived from data in normal controls tested in each center. Therefore, the 
classification of the response given by each investigator was usually 
accepted. The results of bilateral inferior petrosal sinus sampling in­
cluded the study of both basal and CRH-stimulated ACTH secretion in 
most cases. Because at the time the study was planned no patient with 
the ectopic ACTH-syndrome was known to show a baseline ACTH ratio 
greater than 1.4 between the petrosal sinus levels and the peripheral 
venous concentrations, this value was regarded as indicative of pitu- 
itary-dependent hypercortisolism (14,15). The same value has been used 
to indicate the presence of a left or right gradient at the pituitary level
(15).
A detailed explanation of all definitions given in the questionnaire 
was included. All of the questionnaires received were individually 
checked for inconsistencies before statistical analysis.
jStatistical analysis
The major goal of the study was to detect the main prognostic factors 
linked to either failure of treatment or recurrence of Cushing's disease 
after transsphenoidal surgery. For this reason, analysis of the data was 
divided in two parts. In the first, the response of patients was categorized 
as either treatment failure, i.e. patients who needed additional therapy 
for persisting clinical and biochemical hypercortisolism, or as treatment 
success, i,e. patients who did not need any additional treatment as they 
showed clinical remission of the disease and return of a normal sup­
pression of steroid levels during low-dose administration of dexameth­
asone. If recurrence of the disease occurred within 6 months after sur­
gery, patients were considered as treatment failure.
In the second part, we focused on the recurrence of Cushing's disease. 
In this analysis we included only patients who were classified as treat­
ment success after surgery (see above). They were then subdivided into 
patients who had a relapse and those who did not have evidence of 
relapsing Cushing's disease until the last follow-up visit.
Quantitative variables are expressed as mean ± se m . Qualitative data 
were analyzed by the ^ statistic  without Yates' correction. Quantitative 
variables were analyzed by the Mann-Whitney test to avoid assumption 
about the gaussian distribution.
The occurrence of relapse is related to the length of follow-up; there­
fore, the cumulative probability of no relapse during the follow-up was 
estimated by means of survival analysis [product-limit method accord­
ing to Kaplan and Meier (16)1. The differences in the disease-free ex­
perience among the classes of the investigated variables were tested by 
Breslow generalized Wilcoxon test (17).
To obtain reliable estimates, the disease-free curve was stopped at 120 
months, which is when the number of patients remaining at risk was 
approximately less then 5% of the starting sample. As some information 
was not gathered at the time of original diagnosis or treatment, missing 
data were dealt with by carrying out complete case analyses in which 
patients were excluded from particular analyses if their files did not 
contain data on the required variables.
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Results
Patient characteristics
The total number of questionnaires received was 716. After 
careful scrutiny of the data, 668 forms were retained for final 
analysis. The reasons for exclusion of the remaining 48 ques­
tionnaires were the following: patients actually had Nelson's 
disease (n = 10); patients had been operated on after the date 
for inclusion in the study (n = 12); and important data were 
missing (n = 26). A clear preponderance of female patients 
was observed (female/male ratio: 3,32). Mean age at surgery 
was 38.2 ± 0.55 yr (range 8-84 yr, median 38 yr). The esti­
mated interval between onset of the disease and diagnosis of 
Cushing's disease was 53.3 ± 1.82 months (range 5-355 
months, median 40), and the mean interval between diag­
nosis and surgery was 10.2 ±  1.05 months (range 1-342 
months, median 3.4 months). Surgery was performed before 
1981 in 95 patients (14.2%), between 1981 and 1985 in 277 
patients (41.5%), and after 1985 in 296 patients (44.3%).
Mortality and morbidity
Perioperative mortality was defined either as any death 
occurring within 1 month from surgery or as death resulting 
from a complication of operation. The perioperative mortal­
ity rate was 1 .9% (13 patients). Death occurred between 5 and 
134 days after operation. Of the patients who died, 3 were 
operated on before 1981 (3.2%), 6 were operated on between 
1981 and 1985 (2.2%), and 4 were operated on after 1985 
(1.4%). Major complications of surgery were reported in 97 
patients (14.5%) and were distributed unevenly among cured 
and not cured patients. The most frequent adverse events 
were cerebrospinal fluid rhinorrhea (4.6%), diabetes insipi­
dus for at least 6 months (3.0%), meningitis (2 .8%), vascular 
injury or profuse bleeding (1.3%), and pulmonary embolism 
(0.6%). Twenty-two patients experienced 2 or more compli­
cations. The most frequent association was meningitis after 
postoperative cerebrospinal fluid rhinorrhea (7 patients).
Early postoperative results
After operation, 158 patients (23.7%) were considered as 
treatment failure and 510 (76.3%) were judged to be in re­
mission. The percentage of failure varied among the different 
centers from 0% to 47.6% (median 18.2%). When considering 
only centers with at least 20 evaluable patients, the failure 
rate ranged from 7.4%-47.6% (median 1.4,6%). No significant 
association was found between the general demographic 
characteristics of the patients and the occurrence of failure. 
There was a nonsignificant trend toward a declining per­
centage of surgical failures in more recent years (28.4%, 
25.6%, and 20.3% for the periods 1975-1980, 1981-1985, and 
1986-1990, respectively). Previous therapy with drugs, ra­
diotherapy, and partial adrenalectomy, alone or in combi­
nation, reported in 176 patients (26.5%), did not correlate 
with the outcome.
Baseline ACTH, cortisol, and urinary steroid levels were 
not associated with the outcome of surgery. Preoperative 
dynamic testing of ACTH and cortisol secretion with CRH 
and TRH/GnRH was reported in 208 and 100 patients, re­
spectively. Patients with normal or excessive ACTH and 
cortisol response to CRH showed a failure rate (22.9%) that 
was significantly lower than in the group with no response 
(44.0%; P <  0.05). The presence of a paradoxical increase of 
cortisol levels after TRH/GnRH administration, reported in 
27 patients (27%), had a near-significant negative prognostic 
value (percentage of failure in this group 37% vs. 20.5% in the 
group without such response; P <  0.10).
Bilateral sampling of inferior petrosal sinus was per­
formed in 98 patients. The overall failure rate in this group 
(23.5%) was similar to that of patients who did not undergo 
the procedure (23.7%). Seventeen patients did not show a 
positive central-peripheral gradient but they were subjected 
to surgery nonetheless; 6 of them did not achieve remission 
of the disease, In the 3 patients lacking histological confir­
mation of a pituitary adenoma, an ectopic ACTH-syndrome 
was strongly suspected. However, at the last follow-up (4,35, 
and 40 months after surgery), no source of ectopic ACTH 
secretion was detected. In the patients with a gradient, the 
percentage of failure was significantly higher in patients who 
did not have a left or right gradient (50%) than in those who 
did have a left or right gradient (13.3% and 17.9%, respec­
tively; P < 0.05).
Visualization of the adenoma by CT, reported in 281 
(47.7%) of 589 patients, was strongly correlated with a good 
outcome (failure rate of 14.9% as compared to 28.4% and 
29.7% of patients with normal or equivocal findings, respec­
tively; P < 0.001). Analysis of MRI, although performed in 
only 115 patients, confirmed a similar trend (failure rate of 
12.9% in patients in whom the adenoma was identified vs. 
26.4% in patients with no evidence of the tumor; P < 0.10).
Selective adenomectomy, selective adenomectomy with 
wide margins, and hemihypophysectomy had similar failure 
rates of 20.0%, 23.8%, and '19.7%, respectively. Total hypoph- 
ysectomy still carried a failure rate of 32.5%, Failure of sur­
gery was common (69.6%) when the surgeon did not identify 
any lesion at surgery.
Macroadenomas (reported in 20.7% of the patients), ex- 
trasellar extension of the tumor (14.5%), and tumor inva­
siveness (6.7%) as well as the location of the adenoma did not 
influence the outcome of surgery. Lack of histological doc­
umentation of an ACTH-secreting adenoma was more fre­
quent in patients not in remission (47.1% vs. 16.6%; P <  
0.001).
Evidence for an underlying misdiagnosed ectopic ACTH 
syndrome in the group not in remission after surgery was 
sought by reviewing the cause of death of the patients. Five 
of 26 patients died of cancer (metastatic tumor of unknown 
origin, uterine carcinoma, ovarian cancer, breast cancer, and 
metastatic carcinoid) 2, 10, 27, 42, and 57 months after op­
eration, respectively. In 2 additional patients, a clinical sus­
picion of ectopic syndrome was reported. Thus, misdiagno­
sis of ectopic ACTH-syndrome seems to be a possible 
explanation for the therapeutic failure in a small subgroup of 
patients.
Recurrences
The analysis of the recurrences included the 510 patients 
who were considered in remission after operation. One hun­
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dred three patients (20.2%) were either lost to follow-up 
(15.1%) or died (5.1%) while they were still disease-free, after 
a mean follow-up of 24 ± 0.1 months (median = 13 months).
Sixty-five patients (12.7%) had clinical and biochemical 
recurrence of the disease during follow-up. Recurrence oc­
curred after a mean time of 39.3 months (median 33 months) 
within a range of 6-104 months. The overall disease-free 
curve is shown in Fig. 1. There was a constant decline in the 
percentage of patients without relapse, approaching 83% at 
60 months.
Demographic variables did not correlate with the risk of 
recurrence. Only younger age at surgery, i.e. less than 38 yr 
(the median population age), conferred a higher risk of re­
lapse, but the difference was of borderline significance (P = 
0.055). The results of preoperative hormonal studies did not 
correlate with the occurrence of relapse. Only the paradoxical 
cortisol response to TRIT/GnRIT showed a weak but non­
significant (P < 0.10) association with relapse of disease 
(36.8% of patients with such a response vs. 17.9% of those 
without the abnormal response). Patients with preoperative 
visualization of the pituitary tumor by MRI or CT showed 
earlier recurrence after surgery (P <  0.03 and P  -  0.053, 
respectively) (Fig. 1, upper right). Perioperative variables such 
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Fkj. 1. A nalysis of the recurrence of Cushing’s disease in the patients  
who were in  rem ission after transsphenoidal operation. In the u pper  
loft, the disease-free survival in the whole group is  shown (numbers 
in brackets represent patients at risk at the end of each year). In the 
upper  r ig h t , the disease-free survival according to the presence of a 
normal {n =  220) or abnormal (n -  239) pituitary CT scan am ong the 
459 who were exam ined before surgery is reported. Patients w ith  an 
abnormal preoperative CT scan had a higher risk of recurrence, but 
the difference was of borderline significance (P  =  0.053). In th e  low er  
lefty the disease-free survival according to the early postoperative 
morning cortisol level is shown for the 482 patients for whom  the 
result w as available. Patients w ith undetectable (n ~  94) and low 
(n. = 250) cortisol levels had fewer recurrences during follow-up than  
did patients with low-normal (n =  97) and high-normal (n ~  41) 
cortisol levels. The overall difference among the four groups was 
highly significant (P  <  0.0001). In the low er  r ig h t ,  the disease-free  
survival according to the length of glucocorticoid substitution therapy  
is reported for all of the 510 patients who had successful operations. 
Patients who did not need any substitution therapy (n =  82) and those  
who required glucocorticoid replacement for less than 1 yr (n -  248) 
showed a higher risk o f recurrence than did patients treated for more 
than 1 yr (n =  180), The overall difference among the three groups was 
highly significant (P  <  0 .000X).
extrasellar growth of the adenoma, and histologic confirma­
tion were not significantly different between the two groups 
of patients.
Early postoperative assessment of steroid secretion was 
highly predictive of long-term outcome. Recurrences in­
creased from 4.3% in patients with postoperative, undetect­
able circulating cortisol levels to 26.3% in patients with high- 
normal levels (P <  0.0001) (Fig. 1, lower left). The same pattern 
occurred for postoperative urinary steroid measurement (P 
< 0.0001), even though the number of patients investigated 
was lower (n = 266). Early postoperative CRH test was 
performed in only 82 patients. Persistence of a normal or 
exaggerated cortisol response predicted a higher likelihood 
of recurrence (17.5% and 42.9%, respectively, vs. 0% of pa­
tients with no cortisol response; P <  0.01). Need for and 
duration of glucocorticoid substitution therapy were 
strongly and inversely correlated with the occurrence of re­
lapse (P < 0,0001) (Fig. 1, lower right). When replacement 
therapy was needed for more than 1 yr, the probability of 
recurrence of the disease at 5 yr was low (3% vs. 24% for 
glucocorticoid therapy less than 1 year and 47% in patients 
not requiring any substitution therapy).
Discussion
Our survey study allowed us to asses the results of trans­
sphenoidal pituitary surgery in 668 patients throughout Eu­
rope who were operated on for Cushing's disease from 1975 
to 1990. In common with all multicenter and retrospective 
studies, our survey has inherent bias. Because of the great 
variability of methods used in the different countries and 
throughout the study period, we could not perform any 
quantitative analysis of hormonal data. However, the large 
number of patients and the long follow-up allow some con­
clusions to be drawn about immediate and late outcome. Our 
study confirms that transsphenoidal microsurgery is a safe 
procedure in patients with Cushing's disease, with a perio­
perative mortality rate of 1.9%, comparable with that of other 
large series from single institutions (11,18, 19).
The definition of successful operation rested mainly on 
clinical grounds, i.e. remission of signs and symptoms of 
hypercortisolism and no additional requirement for therapy 
to control hypercortisolism for at least 6 months. The latter 
criterion was chosen to lessen the probability of postopera­
tive misclassification such as cyclical Cushing's disease (20). 
By these criteria, 510 patients (76.3%) were in remission of 
disease after operation, a percentage of success similar to that 
reported in other surgical series from single institutions (1 1 , 
13, 18, 19, 21-34; Table 1 ), even though the great variability 
in the definition of cure makes direct comparison of these 
results difficult.
Burch (9), in a multicenter survey carried out in the United 
States in 1983, found a great variability in the remission rates, 
which ranged from 10-100%. In our multicenter study, the 
results were more homogeneous among the participating 
centers (from 52.4%-100%) and showed a trend toward 
higher remission rates in recent years, probably reflecting the 
increasing experience with the diagnosis and therapy of 
Cushing's disease.
TABLE 1. R esults o f transsphenoidal surgery for Cushing’s disease
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Author Year Success rate Recurrences
Mean follow-up 
(Months)
S alassa  e t  aL (21) 1978 16/18 (88.9%) 0/16 (0%) 18
Hardy (22) 1982 63/75 (84.0%) 0/63 (0%) 21
Thom as and Richards (23) 1983 13/16 (81.2%) N ot stated Not stated
Sem ple et al. (24) 1984 17/19 (89.4%) 1/17 (5.9%) 40
Burch (25) 1985 9/14- (64.3%) 1/9 (11.1%) Not stated
Tagliaferri e t  al. (26) 1986 19/23 (75.6%) 2/19 (10.5%) 39
Chandler e t  al, (27) 1987 24/34 (70.5%) N ot stated N ot stated
N akan e e t  al. (28) 1987 86/100 (86.0%)“ 8/86 (9.3%)6 38
G uilhaum e e t  al. (11) 1988 42/61 (68.9%)" 6/42 (14,3%) 24
M am palam  e t  aL  (18) 1988 171/216 (79.2% f 9/171 (5.3%)
m
46
Arnott e t  al. (29) 1990 24/28 (85.7%) 3/24 (12.6%) 22
Burke e t  al. (30) 1990 44/54 (81.5%) 2/44 (4.5%) 56
Post and H abas (31) 1990 29/37 (78.4%) 1/29 (3.4%) Not stated
Tindall e t  al. (19) 1990 46/53 (86.8%) 1/46 (2.1%) 57
Robert and H ardy (32) 1991 60/78 (76.9% / 5 /60  ( 8 .3 % r 77
Tahir and Sheeler (13) 1992 34/45 (75.6%) 7/34 (20.6%) 69
Trainer e t  al. (33)*' 1993 39/48 (81.2%) 3/39 (7.7%),z Not stated
Ram et al. (34)* 1994 205/222 (92.3%) N ot stated Not stated
P resent series 1995 510/668 (76.3%) 65/510 (12.7%) 46
Single series published by participants in  th is survey are not included. 
a N egative predictive factor o f im m ediate  outcome: no adenom a found at operation.
6 N egative predictive factor for recurrence: short duration o f replacem ent therapy. 
e N egative predictive factor o f  im m ediate  outcome: extrasellar adenoma. 
d N egative predictive factor for recurrence: h igher postoperative steroid levels.
* N egative predictive factor for recurrence: no adenom a found at operation. 
f  N egative predictive factor o f im m ed iate  outcome: invasive adenoma. 
tt N egative predictive factor for recurrence; younger age*
Ten patien ts were subjected to repeated  pituitary exploration within 10 days of surgery because of m easurable cortisol levels. 
1 Seventeen  patients underw ent repeat p itu itary surgery 7—46 days after first operation because of persistent hypercortisolism.
Early outcome of surgery was associated with few pre­
operative characteristics. Among hormonal variables, only 
the lack of response to CRH had a predictive negative value. 
A similar result was reported by Pieters and co-workers (12) 
who showed that preoperatively the mean increment of cor­
tisol levels after the administration of CRH was higher in the 
group of successfully operated patients. As the absence of 
cortisol and ACTH response to CRH does not suggest a 
pituitary origin of hypercortisolism (35), the higher failure 
rate in such patients might reflect misdiagnosis of an ectopic 
ACTH-syndrome. On the other hand, 14 of the 25 patients 
with a negative response to CRH had a remission after pi­
tuitary surgery, suggesting that at least 50% of these patients 
had pituitary tumors not responsive to CRH.
As already suggested by Pieters and co-workers (12), pa­
tients with the paradoxical cortisol responsiveness to TRH/ 
GnRH had a trend toward a higher percentage of surgical 
failure, but unfortunately the number of patients who un­
derwent the test (100 subjects) was probably too small to 
allow adequate statistical analysis.
Since the early 1980s, bilateral inferior petrosal sinus sam­
pling has been introduced in order to identify with certainty 
the origin of ACTH hypersecretion (36) and to improve the 
surgical results by selecting the side of hemihypophysec- 
tomy in those patients with a negative pituitary exploration 
(37). The latter expectation, however, has not been corrob­
orated by the same author (36) and by other groups (14,15), 
probably because the diagnostic accuracy in localizing the 
intrapituitary side of the adenoma did not reach the desired 
100%. Our results, although showing no significant differ­
ence in the success rate among patients who did and did not 
undergo the procedure, do not allow definitive conclusions 
to be drawn about the impact of inferior petrosal sinus sam­
pling on surgical results because of the limited number of 
patients available for analysis (98 of 668).
Preoperative visualization of the pituitary lesion by either 
CT scan or MRI was associated with a better outcome, prob­
ably because identification and removal of the pathological 
tissue at operation was easier. On the other hand, this ad­
vantage was counterbalanced by a higher rate of tumor re­
currence (see below). These findings suggest that additional 
refinements of neuroradiological tools, leading to a more 
precise intrapituitary localization of small tumors in Cush­
ing's disease, should bring an important amelioration of the 
early surgical results in thè future.
Operative variables did not influence the outcome of sur­
gery, with the exception of a negative pituitary exploration 
and a negative histopathology. In the past, total hypophy- 
sectomy has been advocated as the procedure of choice in 
patients with Cushing's disease (23) because it was pre­
sumed that the improvement of postoperative results would 
counterbalance the sacrifice of anterior pituitary function. 
Our survey clearly shows that compared with hemi- or total 
hypophysectomy, a more conservative surgical approach 
does not reduce the success rate. At variance with data in 
GH- and PRL-se ere ting tumors (38,39), other variables such 
as tumor size, invasiveness, and extrasellar extension did not 
significantly affect the results, probably because only a mi­
nority of ACTH-secreting tumors possessed such features.
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Thus, it may be necessary to analyze many more cases in 
order to detect a significant difference for these variables.
Until recently, the recurrence of Cushing's disease after 
successful operation was regarded as a rare event. Indeed, 
many surgical series, especially the oldest ones, reported few 
late relapses (Table 1 ). On die contrary, in recent years it has 
become clear that recurrence of the disease is more frequent 
than was previously thought (Table 1). In our study, 65 
(12.7%) of 510 patients in remission after surgery relapsed 
during a mean follow-up period of 57 months. Interestingly, 
the occurrence of relapses did not show any time-related 
plateau but did show a progressive upward trend, as first 
suggested by Guilhaume and co-workers (11 ). This fact 
stresses the need for continued and careful monitoring of 
patients.
To date, and because of the few cases studied in each single 
surgical series, no clear preoperative characteristic has 
emerged as a strong predictive factor for the occurrence of 
relapse. Only younger age at surgery was suggested as car­
rying a higher risk of recurrence of disease (32). Our results 
showing a higher risk of relapse in younger patients lend 
support to this suggestion. However, Magiakou and co­
workers (40) recently reported a low recurrence rate (6.3%) 
in a group of children with Cushing's disease who were 
operated on at the NIH.
Paradoxical responsiveness to TRH/GnRIT had a weak 
but nonsignificant correlation with recurrence of disease* 
However, a larger sample of patients is needed before de- 
finitive conclusions about the predictive value of the test can 
be drawn. Visualization of the adenoma by neuroradiologi- 
cal studies was correlated with a higher risk of relapse. To 
explicate the divergence between the immediate and late 
results, it is likely that adenomas visible at pituitary imaging 
are usually large enough to be easily detected by the surgeon, 
which explains the better immediate postoperative results. 
On the other hand, the larger the tumor, the higher the 
probability that some adenomatous cells may remain and 
eventually cause regrowth of the tumor.
Early pos topera ti ve results were strongly associated with 
late outcome. Increasing rates of recurrence were associated 
in ascending order with the postoperative levels of serum 
and urinary steroids, as previously suggested by Pieters and 
co-workers (12). Similarly, the persistence of a cortisol re­
sponse after CRH administration was correlated with a 
higher risk of relapse. The same finding was reported pre­
viously (12, 41, 42). After operation, normal secretion of 
ACTIT and cortisol, either at baseline or in response to CRH, 
might suggest that residual adenomatous tissue is still 
present, as normal corticotrophs should remain completely 
suppressed by the preoperative chronic hypercortisolism 
(33). On the basis of this assumption, Trainer et al. (33) rec­
ommended early reoperation or radiotherapy in patients 
with detectable steroid levels after surgery. However, be­
cause in our series only 33 of 135 patients with normal post­
operative circulating cortisol levels had a relapse, we em­
phasize that normal steroid levels after surgery are not 
necessarily followed by recurrence of the disease, making the 
aggressive policy of early reoperation and radiotherapy 
highly questionable, inasmuch as they often result in pan­
hypopituitarism and permanent diabetes insipidus (33).
It is well known that after surgery most patients show 
transient secondary adrenal insufficiency requiring replace­
ment therapy with glucocorticoids for variable periods of 
time (43). Our study clearly shows that the longer the need 
for glucocorticoid substitution, the higher the probability 
that the patient will remain free of disease in the long term 
(Fig. 1, lower right). When substitution therapy was needed 
for longer than 1 yr, the percentage of disease-free patients 
at 5 yr was 97%, whereas it declined to 76% and 53%, re­
spectively, when such therapy was required for less than 1 
yr or not at all.
In conclusion, transsphenoidal surgery is a safe and ef­
fective treatment modality in patients with Cushing's dis­
ease, as confirmed in our multicenter study by the early 
success rate of about 76%. Moreover, our results show that 
recurrence of Oashing's disease is not a discrete phenome- 
non, inasmuch as it occurs progressively over the years with­
out any apparent tendency to plateau. Hypocortisolism after 
surgery is the most important factor predicting a good long- 
term outcome: the longer the need for glucocorticoid re- 
placement, the lower the probability of relapse. However, 
although a careful follow-up is mandatory, early reoperation 
is not recommended in patients with normal steroid levels 
postoperatively in view of the high percentage of those who 
do not relapse.
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